Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept for Retinal Nonperfusion in Diabetic Retinopathy
NCT03006081Phase 2Completed
- Sponsor
- Asan Medical Center
- Start
- Apr 2016
- Primary completion
- Aug 2018
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of aflibercept in diabetic retinopathy (DR), sponsored by Asan Medical Center. Primary endpoint: Improvement of retinal nonperfusion at 1 year. Started Apr 2016; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic retinopathy (DR)
Beyond the preview
Go deeper on NCT03006081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03006081.